

6 December 2002

Update on Mycograb® Phase II trial

6 December, 2002 – Manchester, UK: *NeuTec* Pharma plc, the biopharmaceutical company targeting drug-resistant infections, announces today that the target for recruitment into the first stage of its double-blinded Phase II clinical trial of Mycograb® has been reached. Site and patient recruitment have recently been increased with the result that 21 patients have now been entered into the trial.

Mycograb® is a treatment for life-threatening invasive candidiasis, a yeast infection, which can affect virtually any part of the body and is the fourth most common cause of bloodstream infections.

There have been no Mycograb-related serious adverse events reported and the pharmacokinetic data confirms the appropriateness of the current dosing regimen for candida infections. The achievement of this important milestone has allowed the Company to progress to the next and larger stage of the study. Additionally, the pharmacokinetic data generated and the drug tolerance profile from this first study will be used as part of an IND application to the Food and Drug Administration (“FDA”) in the US.

Recruitment into the trial will continue at the 38 European sites which have agreed to take part in the study. Of these, 23 have received ethical approval from the relevant authorities and 18 are actively participating in the trial.

For further details please contact:

NeuTec Pharma plc

Andrew King, Finance Director 07771 867890

Financial Dynamics

Jonathan Birt / Samantha Robbins 020 7831 3113